Safety Outcomes for JEMPERLI Monotherapy From the GARNET Trial

Safety profile established over more than 2 years1

Adverse reactions (≥10%) in patients with dMMR endometrial cancer who received JEMPERLI in GARNET

GARNET adverse reactions table
GARNET adverse reactions table

Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03.

*Intent-to-treat population (N=150).

Includes fatigue and asthenia.

Includes anemia, decreased hemoglobin, iron deficiency, and iron deficiency anemia.

§Includes rash, rash maculo-papular, rash pruritic, erythema, and pemphigoid.

Includes increased alanine aminotransferase, increased aspartate aminotransferase, increased transaminases, and hypertransaminasemia.

dMMR=mismatch repair deficient.

10% of patients permanently discontinued therapy due to adverse reactions1

  • Adverse reactions leading to discontinuation were increased transaminases, sepsis, bronchitis, pneumonitis, rash, pruritus, pancreatitis, encephalitis, and nephritis (15 patients total)1
  • The most common adverse reactions (≥20%) were fatigue/asthenia, anemia, nausea, diarrhea, constipation, vomiting, and rash1
  • Serious adverse reactions occurred in 38% of patients receiving JEMPERLI, including (>2% of patients) urinary tract infection (4%), sepsis (3.3%), acute kidney injury (2.7%), and abdominal pain (2.7%)1
  • A fatal adverse reaction occurred in one patient (0.7%) who received JEMPERLI, due to concurrent immune-mediated encephalitis and urinary tract infection1

Laboratory abnormalities from the GARNET trial1

Laboratory abnormalities that worsened from baseline to Grade 3 or 4 occurring in ≥1% of patients with dMMR endometrial cancer receiving JEMPERLI in GARNET

GARNET laboratory abnormalities table
GARNET laboratory abnormalities table

Intention-to-treat population (N=150).


Consists of new onset of laboratory abnormality or worsening of baseline laboratory abnormality.

Icon: JEMPERLI (dostarlimab-gxly) Support

Learn about support for
JEMPERLI at every step

Pie chart icon

See the GARNET trial results

Icon: JEMPERLI (dostarlimab-gxly) Dosing and Administration

Learn about JEMPERLI dosing